At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
PF-07321332/ritonavirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single Center, Open-label Study of PF-07321332 Administrated as Multiple Oral Doses in Healthy Chinese Participants.
In Brief
A Phase 1 clinical trial evaluating PF-07321332/ritonavir for Healthy Participants. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332 when PF-07321332 and ritonavir are given to healthy adult Chinese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
Enrollment StartMar 2022
First PostedApr 2022
Primary CompletionApr 2022
TodayJul 2026
First PostedApr 21, 2022
Enrollment StartMar 10, 2022
Primary CompletionApr 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 4.2 years ago
Interventions
PF-07321332/ritonavirdrug
PF-07321332/ritonavir will be given by mouth two times a day for 10 days